Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.

Cell cycle (Georgetown, Tex.) - 1 Jan 2015

McVeigh Terri P, Jung Song-Yi, Kerin Michael J, Salzman David W, Nallur Sunitha, Nemec Antonio A, Dookwah Michelle, Sadofsky Jackie, Paranjape Trupti, Kelly Olivia, Chan Elcie, Miller Nicola, Sweeney Karl J, Zelterman Daniel, Sweasy Joann, Pilarski Robert, Telesca Donatello, Slack Frank J, Weidhaas Joanne B

Abstract excerpt

The KRAS-variant is a biologically functional, microRNA binding site variant, which predicts increased cancer risk especially for women. Because external exposures, such as chemotherapy, differentially impact the effect of this mutation, we evaluated the association of estrogen exposures, breast cancer (BC) risk and tumor biology in women with the KRAS-variant. Women with BC (n = 1712), the subset with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Replacement Therapy

Share to Estrogens

Share to Genetic Variation

Share to Proto-Oncogene Proteins p21(ras)

Share to Risk Factors

Share to Substance Withdrawal Syndrome

Source

Open in PubMed Open full text

Identifiers

PMID: 25961464
DOI: 10.1080/15384101.2015.1041694
PMCID: PMC4614527

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.PMID 25961464Read ↗

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.Semantic proximity Read ↗

KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.Semantic proximity Read ↗

The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.Semantic proximity Read ↗

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.Semantic proximity Read ↗

Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.Semantic proximity Read ↗

Mesenchymal tumor cells drive adaptive resistance of Trp53-/- breast tumor cells to inactivated mutant Kras.Semantic proximity Read ↗

KRAS 3'-UTR variants and stratification of breast-cancer risk.Semantic proximity Read ↗

Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.Semantic proximity Read ↗

A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.Semantic proximity Read ↗

Adaptive selection of p53 mutation metaplastic phenotypes in estrogen-independent progression of ER+ tumors: A mechanism for acquired resistance to hormonal therapySemantic proximity Read ↗

Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER⁺ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast CancerSemantic proximity Read ↗

Steroid receptor variants and their potential role in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.